Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

NCT02868073 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Norovirus Gastroenteritis

Interventions

BIOLOGICAL: VXA-G1.1-NN (high dose) Oral Vaccine Tablet
OTHER: VXA Placebo Tablets
BIOLOGICAL: VXA-G1.1-NN (low dose) Oral Vaccine Tablet

Sponsor

Vaxart